ClinConnect ClinConnect Logo
Search / Trial NCT01689428

Ism1 Versus EmbryoGen Media for Embryo Culture in Previous Pregnancy Loss Cases

Launched by BIOGENESI · Sep 17, 2012

Trial Information

Current as of May 08, 2025

Unknown status

Keywords

Ivf Embryo Culture Ongoing Pregnancy Rate Ongoing Implantation Rate Miscarriage

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • - At least one (maximum 3) miscarriage and/or biochemical pregnancy after ART treatment
  • Exclusion Criteria:
  • Frozen spermatozoa
  • Frozen oocytes
  • women with PCO and PCOS
  • women with more than 4 ART treatments

About Biogenesi

Biogenesi is a leading biopharmaceutical company dedicated to advancing innovative therapies that address unmet medical needs. With a strong emphasis on research and development, Biogenesi focuses on the discovery and commercialization of novel treatments for various complex diseases. The company is committed to enhancing patient outcomes through rigorous clinical trials and collaborations with healthcare professionals, ensuring that its products are not only effective but also safe and accessible. Biogenesi's mission is to transform healthcare through science and innovation, ultimately improving the quality of life for patients around the world.

Locations

Monza, Mb, Italy

Patients applied

0 patients applied

Trial Officials

Mariabeatrice Dal Canto, PhD

Principal Investigator

Biogenesi Reproductive medicine Centre

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials